BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 MAGNITUDE study.

Olema Pharmaceuticals, Inc. announced results from a Phase 2 clinical study of palazestrant, the Company’s complete estrogen receptor antagonist and selective ER degrader, for the treatment of metastatic ER+/HER2- breast cancer.

Sutro Biopharma, Inc. announced initial results from a Phase 1 dose-expansion study of luveltamab tazevibulin, a novel Folate receptor alpha -targeting ADC, in patients with endometrial cancer, in a mini oral presentation at the 2023 European Society For Medical Oncology Congress in Madrid, Spain.

Amgen announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® in combination with Vectibix®.

Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan plus durvalumab showed that the combination demonstrated durable tumor responses and no new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer with six months additional follow-up from the previous data cut-off.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin -unresponsive, high-risk non-muscle-invasive bladder cancer, who are ineligible for, or decline, radical cystectomy, showed that 77 percent of patients, 58-90]) achieved a complete response.

HOOKIPA Pharma Inc. presented updated data from its ongoing Phase 2 trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic Human Papillomavirus 16-positive head and neck cancer.

Arvinas, Inc. announced the presentation of interim data from the Company’s Phase 1/2 clinical trial for bavdegalutamide, a novel PROTAC® protein degrader targeting the androgen receptor, in a poster session at the European Society for Medical Oncology Congress being held in Madrid from October 20 – 24, 2023.

Seagen Inc. and Genmab A/S announced results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy.

Jacobio Pharma is pleased to announce that the clinical data of glecirasib in combination with JAB-3312 was published in the form of a proffered paper presentation at the 2023 European Society for Medical Oncology Congress.